Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections

Antiviral Research

Volumn 96, Issue 2, 2012, Pages 130-137

  Escuret, Vanessa ^a,b   Cornu, Catherine ^a,b,d   Boutitie, Florent ^a,e   Enouf, Vincent ^c   Mosnier, Anne ^h   Bouscambert Duchamp, Maude ^a,b   Gaillard, Ségolène ^a,b,d   Duval, Xavier ^d,f   Blanchon, Thierry ⁱ   Leport, Catherine ^f,g   Gueyffier, François ^a,b,d   Van Der Werf, Sylvie ^c   Lina, Bruno ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSTITUT PASTEUR   (France)

^d INSERM   (France)

^e UNIVERSITÉ DE LYON   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h Réseau des Groupes Régionaux d'Observation de la Grippe GROG Coordination Nationale   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

Author keywords

Combination therapy; Influenza A(H1N1)pdm09 virus; Oseltamivir; Pandemic; Zanamivir

Indexed keywords

AMANTADINE; LANSOPRAZOLE; OSELTAMIVIR; ZANAMIVIR;

2009 H1N1 INFLUENZA; ADULT; ARTICLE; CHILL; CLINICAL ARTICLE; COUGHING; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEMALE; FRANCE; GASTROINTESTINAL DISEASE; GENE MUTATION; HEADACHE; HUMAN; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NIGHTMARE; NOSE OBSTRUCTION; NOSE SMEAR; OTITIS; PANDEMIC; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SORE THROAT; STOMACH PAIN; SYMPTOM; VIRUS DETECTION; VIRUS EXCRETION; VIRUS LOAD; VOMITING;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NASAL MUCOSA; OSELTAMIVIR; TREATMENT OUTCOME; VIRUS SHEDDING; YOUNG ADULT; ZANAMIVIR;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 84867235710     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.08.002     Document Type: Article

References (28)

1. Boltz D.A., Aldridge J.R., Webster R.G., Govorkova E.A. Drugs in development for influenza. Drugs 2010, 70:1349-1362.
2. Carr M.J., Sayre N., Duffy M., Connell J., Hall W.W. Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A(H1N1) viruses. J. Virol. Methods 2008, 153:257-262.
3. Cheng P.K., Wong K.K., Mak G.C., Wong A.H., Ng A.Y., Chow S.Y., Lam R.K., Lau C.S., Ng K.C., Lim W. Performance of laboratory diagnostics for the detection of influenza A(H1N1)v virus as correlated with the time after symptom onset and viral load. J. Clin. Virol. 2010, 47:182-185.
4. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., Gubareva L.V., Xu X., Bridges C.B., Uyeki T.M. Emergence of a novel swine-origin influenza A(H1N1) virus in humans. N. Engl. J. Med. 2009, 360:2605-2615.
5. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., Shu Y., Gubareva L.V., Cox N.J., Klimov A.I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 2007, 196:249-257.
6. Duchamp M.B., Casalegno J.S., Gillet Y., Frobert E., Bernard E., Escuret V., Billaud G., Valette M., Javouhey E., Lina B., Floret D., Morfin F. Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR: is viral quantification useful?. Clin. Microbiol. Infect. 2010, 16:317-321.
7. Duval X., van der Werf S., Blanchon T., Mosnier A., Bouscambert-Duchamp M., Tibi A., Enouf V., Charlois-Ou C., Vincent C., Andreoletti L., Tubach F., Lina B., Mentre F., Leport C. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010, 7:e1000362.
8. Escuret V., Ferraris O., Lina B. The antiviral resistance of influenza virus. Therapy 2011, 8:741-762.
9. Ferraris O., Kessler N., Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res. 2005, 68:43-48.
10. Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38:143-151.
11. Hayden F.G., Treanor J.J., Fritz R.S., Lobo M., Betts R.F., Miller M., Kinnersley N., Mills R.G., Ward P., Straus S.E. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. Jama 1999, 282:1240-1246.
12. Hill-Cawthorne G.A., Schelenz S., Lawes M., Dervisevic S. Oseltamivir-resistant pandemic (H1N1) 2009 in patient with impaired immune system. Emerg. Infect. Dis. 2010, 16:1185-1186.
13. Hoopes J.D., Driebe E.M., Kelley E., Engelthaler D.M., Keim P.S., Perelson A.S., Rong L., Went G.T., Nguyen J.T. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS One 2011, 6:e29778.
14. Ison M.G., Gubareva L.V., Atmar R.L., Treanor J., Hayden F.G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 2006, 193:760-764.
15. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
16. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., Hay A.J., Zambon M.C. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 2008, 13.
17. Meijer A., Lackenby A., Hungnes O., Lina B., van-der-Werf S., Schweiger B., Opp M., Paget J., van-de-Kassteele J., Hay A., Zambon M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 2009, 15:552-560.
18. Nguyen J.T., Hoopes J.D., Le M.H., Smee D.F., Patick A.K., Faix D.J., Blair P.J., de Jong M.D., Prichard M.N., Went G.T. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5:e9332.
19. Nguyen J.T., Smee D.F., Barnard D.L., Julander J.G., Gross M., de Jong M.D., Went G.T. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One 2012, 7:e31006.
20. Petersen E., Keld D.B., Ellermann-Eriksen S., Gubbels S., Ilkjaer S., Jensen-Fangel S., Lindskov C. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand. J. Infect. Dis. 2011, 43:495-503.
21. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443:45-49.
22. Tamura D., Sugaya N., Ozawa M., Takano R., Ichikawa M., Yamazaki M., Kawakami C., Shimizu H., Uehara R., Kiso M., Kawakami E., Mitamura K., Kawaoka Y. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin. Infect. Dis. 2011, 52:432-437.
23. Tramontana A.R., George B., Hurt A.C., Doyle J.S., Langan K., Reid A.B., Harper J.M., Thursky K., Worth L.J., Dwyer D.E., Morrissey C.O., Johnson P.D., Buising K.L., Harrison S.J., Seymour J.F., Ferguson P.E., Wang B., Denholm J.T., Cheng A.C., Slavin M. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus. Aust. Emerg. Infect. Dis. 2010, 16:1068-1075.
24. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., Singh S., Kinnersley N., Ward P., Mills R.G. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. Jama. 2000, 283:1016-1024.
25. Whitley R.J., Hayden F.G., Reisinger K.S., Young N., Dutkowski R., Ipe D., Mills R.G., Ward P. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 2001, 20:127-133.
26. WHO, 2010. Weekly update on oseltamivir resistance to influenza H1N1 (2009) viruses. Available from Accessed January 03, 2011. http://www.who.int/csr/disease/influenza/2010_12_29_weekly_web_update_oseltamivir_resistance.pdf.
27. WHO, 2011. Weekly epidemiological record. Recommended composition of influenza virus vaccines for use in the 2011-2012 northern influenza season. Available from Accessed June 28, 2011. 86, 81-92. http://www.who.int/wer/2011/wer8610.pdf.
28. Wong S.C., Chan J.K., Lee K.C., Lo E.S., Tsang D.N. Development of a quantitative assay for SARS coronavirus and correlation of GAPDH mRNA with SARS coronavirus in clinical specimens. J. Clin. Pathol. 2005, 58:276-280.